SYNOPSIS

AMYLIN PHARMACEUTICALS: A study showed that adding Symlin, a synthetic analog of the human hormone amylin improve glucose control.in Type 2 diabetes. Good News

XOMA (XOMA): The firm plans new clinical tests for an acne drug that it reformulated after an earlier trial.

Experience and sophistication are paying off for this firm. Xoma is determined to use its experience and science towards saving valuable products and advancing them in clinical trials after fathoming the reasons for their previous failures. Xoma is determined not to leave behind any drug from its BPI protein technology. The acne gel is is the second drug that the firm believes it is valuable and worth pursuing.

TRIMERIS (TRMS) and F. Hoffmann-La Roche Ltd ("Roche") extended their research agreement by additional two years, Why? Because the next Generation Fusion Inhibitor ("NGFI") peptides co-developed by these two firms is showing promise. The cost and the profit will be split between the two firms. Good News

ANORMED (ANOR) will begin trading on the NASDAQ under the symbol "ANOR".The previous Amex Symbol was AOM.

DYAX (DYAX) will license its antibody phage display libraries to Switzerland-based Serono SA for the discovery and development of therapeutic antibodies. Dyax will receive license fees and full-time employee payments from Serono, as well as milestone payments and royalties based on net sales from any products developed from Dyax's libraries. Good News

Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: http://www.sec.gov/consumer/cyberfr.htm